Although the anti‐tumour effects of toceranib are comparable to those of vinblastine in canine MCTs with or without KIT mutations (Thamm et al., 2020), the relationship between the therapeutic response to toceranib and KIT mutation status in feline MCT remains unclear (Berger et al., 2018; Hasegawa et al., 2022). This evidence concerns the gene KIT and neoplasm.